Profund Advisors LLC Acquires Shares of 4,740 BeOne Medicines Ltd. – Sponsored ADR $ONC

Profund Advisors LLC acquired a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the second quarter, HoldingsChannel.com reports. The fund acquired 4,740 shares of the company’s stock, valued at approximately $1,147,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Caitong International Asset Management Co. Ltd acquired a new position in BeOne Medicines in the 2nd quarter worth about $28,000. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines in the 2nd quarter valued at $39,000. Signaturefd LLC purchased a new position in BeOne Medicines during the second quarter valued at $49,000. Parallel Advisors LLC purchased a new stake in shares of BeOne Medicines during the second quarter worth about $59,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth about $121,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeOne Medicines Trading Up 4.4%

Shares of ONC stock opened at $343.65 on Wednesday. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $355.30. The firm has a market cap of $37.68 billion, a PE ratio of 673.82 and a beta of 0.31. The company has a 50-day moving average of $327.61 and a two-hundred day moving average of $289.50. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17.

Analyst Ratings Changes

A number of equities analysts have commented on ONC shares. Barclays began coverage on BeOne Medicines in a report on Thursday, September 18th. They set an “overweight” rating and a $385.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. lifted their price target on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Finally, Citizens Jmp lifted their target price on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $357.33.

Insider Buying and Selling

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the company’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $337.00, for a total transaction of $898,105.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO John Oyler sold 27,803 shares of BeOne Medicines stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total value of $9,055,715.13. The SEC filing for this sale provides additional information. Insiders have sold 96,203 shares of company stock valued at $30,923,233 over the last quarter. 6.62% of the stock is owned by corporate insiders.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.